Singapore Research Organizations Team up to Advance Drug Discovery Using Brain Tumor Stem Cells

摘要

Lilly Singapore Centre for Drug Discovery (LSCDD); Singapore's National Neuroscience Institute (NNI), and the Singapore Institute for Clinical Sciences (SICS), have teamed up to advance drug discovery using adult brain tumour stem cells. NNI is one ofthe institutions of SingHealth, the largest public healthcare group in Singapore. LSCDD, a wholly owned subsidiary of the US-based biopharmaceutical company, Eli Lilly and Company has recently expanded its facility at the Biopolis, and has cancer as one of its disease areas of focus. SICS is one of the research institutes of Singapore's A*STAR (Agency for Science, Technology and Research).